Evidence map›Paper›PMID 42848227›Full record

SynthesisJournal of neurology2026

Efficacy and safety of PCSK9 inhibitors combined with statins in acute ischemic stroke: a systematic review and meta-analysis.

Xiaozuo Lin, Rongxin He, Xiaohan Zhang, Yinan Zeng, Tian Wang, Simin Chen, Linkun Chen, Man Luo

Abstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xiaozuo Lin *Department of Neurology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Rongxin He *Department of Neurology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Xiaohan ZhangDepartment of Neurology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Yinan ZengDepartment of Neurology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Tian WangDepartment of Neurology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Simin ChenDepartment of Neurology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Linkun ChenDepartment of Neurology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Man LuoDepartment of Neurology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China. luoman@gxmu.edu.cn.ORCID http://orcid.org/0000-0002-0543-9763

Funding

Guangxi Key Research and Development Program AB24010094Guangxi Medical and Health Appropriate Technology Development and Application Project S2022091National Natural Science Foundation of China 82260241Natural Science Foundation of Guangxi Province 2020GXNSFAA259053Natural Science Foundation of Guangxi Province 2026GXNSFAA00640608
6 · The paper itself

Abstract

backgroundAcute ischemic stroke (AIS) imposes a substantial global burden of mortality and long-term disability. As novel lipid-modulating agents, proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) have demonstrated therapeutic benefits across a wide range of cardiovascular patient groups, but dedicated evidence in AIS cohorts has not been quantitatively synthesized. We therefore conducted this meta-analysis to compare the efficacy and safety of PCSK9i combined with statin therapy versus statin monotherapy among patients with AIS.

methodsWe searched seven databases from inception to May 31, 2026 for randomized controlled trials (RCTs). Two reviewers independently performed study screening, data extraction, and risk-of-bias assessment. Dichotomous and continuous outcomes were synthesized using odds ratios (OR) and mean differences (MD), respectively. Heterogeneity was assessed via the I

resultsCompared with statin monotherapy, PCSK9i combination therapy significantly improved functional independence (modified Rankin Scale (mRS) 0-2: OR = 2.17, 95% CI 1.29-3.64, P = 0.003, I

conclusionsPCSK9i adjunctive therapy may improve functional recovery and reduce stroke recurrence in AIS patients receiving statins, with acceptable short-term safety; however, the current evidence remains preliminary and requires confirmation in larger, adequately powered randomized trials.

Indexed as

Hydroxymethylglutaryl-CoA Reductase InhibitorsIschemic StrokeOutcome Assessment, Health CarePCSK9 InhibitorsDrug Therapy, CombinationHumansProprotein Convertase 9Hydroxymethylglutaryl-CoA Reductase InhibitorsPCSK9 InhibitorsPCSK9 protein, humanProprotein Convertase 9Acute ischemic strokeMeta-analysisPCSK9 inhibitorsStatins

Identifiers

PMID42848227

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.